A patient-derived ovarian cancer organoid platform to study susceptibility to natural killer cells
Marisa Mercadante, Armin SchebeniD, Jacob Estrada, Jan Savas-Carstens, William Sullivan, Nicholas Housel, Maria L. Sapar, Tatiana Volpari, Jax Hebner, Tomasz Rusielewicz, Frederick J. MonsmaiD, Stefan SemrauiD, Yinan Wang, Laura A. MartiniD
Abstract
Intratumoral heterogeneity drives therapy resistance and relapses in advanced stage cancers, such as ovarian cancer. Here, we present a live cell imaging assay using patient-derived ovarian cancer organoids for real time capture and quantification of natural killer cell-mediated apoptotic events in >500 organoids simultaneously. Our assay revealed significant inter- and intratumor response heterogeneity and identified a rare resistant organoid population, opening avenues to test immunomodulatory strategies that overcome resistance.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 5
- FWCI
- 1.86
- Field percentile
- top 13%
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- A Scalable 3D High-Content Imaging Protocol for Measuring a Drug Induced DNA Damage Response Using Immunofluorescent Sub-nuclear γH2AX Spots in Patient Derived Ovarian Cancer Organoids
Hakan Keles, Christopher Schofield, … Lisa Mohamet·ACS Pharmacology & Translational SciencePeer-reviewed·Dec 12, 2022
- Ovarian cancer-on-chip for patient-specific profiling of treatment responses to sequential chemotherapy and PD-L1 blockade
Sarah Plöger, Nicole Anderle, … Peter Loskill·bioRxiv·Jul 24, 2026
- Organoid-based modeling of platinum resistance identifies KRT17 as both a response mediator and biomarker for targeted therapy in ovarian cancer
Juliane Reichenbach, Juliana Schmid, … Mirjana Kessler·bioRxiv·Mar 10, 2025
- Organoid Models Derived from Primary Tumors and Patient-Derive Xenograft Tumors Reflect Platinum Sensitivity of Ovarian Cancer Patients
Parisa Nikeghbal, Dorsa Zamanian, … Mara P. Steinkamp·BMC CancerPeer-reviewed·Sep 30, 2025
- Recognition of Ovarian Tumor-Derived Non-canonical Peptide Induces Memory-Like Features in Natural Killer Cells
Yizhe Sun, Yaroslav Kaminskiy, … Dhifaf Sarhan·bioRxiv·Sep 15, 2025
- Targeting dormant ovarian cancer cells in vitro and in an in vivo model of platinum resistance
Z. Huang, E. Kondoh, … S. K. Murphy·bioRxiv·Jul 26, 2019